Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Research and Innovation Action · Running

PREDICTOM Prediction of Alzheimer’s Disease Using an Ai Driven Screening Platform

Coordinator
Helse Stavanger Hf, Norway
Runs
1 November 2023 to 31 October 2027
Status
Running
EU funding
€8.4m
Total cost
€17.6m
Partners
37 organisations in 15 countries
Type
Research and Innovation Action
Grant agreement
101132356

What the project is doing

In the project's own words, from its summary on CORDIS.

Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease, but the health care system is not ready for this new scenario. There is an urgent need, therefore, to establish scalable, cost-efficient diagnostic markers, tools and procedures that can identify people at increased risk, at point of care for stratification into personalized interventions to prevent or delay dementia.

PREDICTOM will develop an open-source, interoperable and customisable biomarker screening platform, utilizing an existing online resource to save time and money, to generate an evidence base for general population screening for AD and related disorders. We will bring diagnostics closer to the patient by examining the feasibility of using samples which can be obtained at home (e.g. finger-prick blood, saliva (for genetics and epigenetics) and stool for microbiom) for diagnostic biomarker analysis.

We will also evaluate innovative technologies for disease risk identification, including digital technologies and novel MRI, EEG, eye tracking, and blood-based biomarkers. The platform will use artificial intelligence models to analyse data from all biomarkers to identify users at high risk of developing dementia and to direct them to personalized intervention to prevent further cognitive decline and development of dementia.

We will seek to facilitate a change in current healthcare practice for early diagnosis of AD through development of new clinical practice guidelines based on evidence generated in the project. By improving the ease of identification of those with early signs of dementia we expect to have a significant impact on personal and financial burden of dementia in Europe and across the world.

Who is involved

OrganisationCityCountryRole
Helse Stavanger HfStavangerNorwayCoordinator
Joanneum Research Forschungsgesellschaft MbhGrazAustriaParticipant
Icometrix NVLeuvenBelgiumParticipant
Vrije Universiteit BrusselBruxelles / BrusselBelgiumParticipant
Universite De GeneveGeneveSwitzerlandAssociatedpartner
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Ge Healthcare GmbHDusseldorfGermanyParticipant
Klinikum Der Ludwig-Maximilians-Universitat MunchenMunchenGermanyThird party
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Siemens Healthcare GmbHErlangenGermanyParticipant
Siemens Healthineers AGForchheimGermanyParticipant
Universitatsklinikum ErlangenErlangenGermanyParticipant
Gn Hearing ASBallerupDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad ValencianaValenciaSpainParticipant
Neuroelectrics Barcelona SLBarcelonaSpainAssociatedpartner
Starlab Barcelona SLBarcelonaSpainAssociatedpartner
Ge Medical Systems ScsBucFranceThird party
Qairnel SASBourg-La-ReineFranceParticipant
Ge Healthcare Magyarorszag KftBudapestHungaryThird party
Pharmacoidea Fejleszto Es Szolgaltato KftSzegedHungaryParticipant
Siemens Healthcare Private LimitedVikhroli EastIndiaThird party
Siemens Healthcare Private LimitedVikhroli EastIndiaThird party
Alzheimer EuropeSenningerbergLuxembourgParticipant
Stichting LygatureUtrechtNetherlandsParticipant
King's College LondonLondonUnited KingdomAssociatedpartner
Muhdo Health LtdIpswichUnited KingdomParticipant
National Institute for Health and Care ExcellenceManchesterUnited KingdomAssociatedpartner
The University of ExeterExeterUnited KingdomAssociatedpartner
Altoida IncWilmingtonUnited StatesParticipant
Alzpath IncWilmingtonUnited StatesParticipant
Braincheck IncAustinUnited StatesParticipant
Siemens Healthcare Diagnostics Inc.TarrytownUnited StatesThird party
Siemens Healthcare Diagnostics Inc.TarrytownUnited StatesThird party
Siemens Medical Solutions Usa IncMalvern PaUnited StatesThird party
Siemens Medical Solutions Usa IncMalvern PaUnited StatesThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI